Issue Fee. (a) As initial payment for the rights received under this Agreement with respect to CTL Products, Licensee paid to Institute a fixed fee of three million dollars ($3,000,000) (the “Issue Fee”) within fifteen (15) business days following the Original Effective Date. The Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee. The Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute. (b) As initial payment for the rights received under this Agreement with respect to BKV-Specific CTL Products, Licensee will pay to Institute a fixed fee of [ * ] (the “BKV Issue Fee”) within fifteen (15) business days following the Execution Date. The BKV Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee. The BKV Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.
Appears in 1 contract
Sources: Exclusive License Agreement (Atara Biotherapeutics, Inc.)
Issue Fee. (a) As initial payment for the rights received under this Agreement with respect to CTL Products, Licensee paid to Institute a fixed fee of three million dollars ($3,000,000) (the “Issue Fee”) within fifteen (15) business days following the Original Effective Date. The Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee. The Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.
(b) As initial payment for the rights received under this Agreement with respect to BKV/JCV-Specific CTL Products, Licensee will pay paid to Institute a fixed fee of [ * [***] (the “BKV BKV/JCV Issue Fee”) within fifteen (15) business days following the Execution First Restatement Date. The BKV BKV/JCV Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee. The BKV BKV/JCV Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.
(c) As initial payment for [***], Licensee paid to Institute [***] within fifteen (15) business days [***].
Appears in 1 contract
Sources: Exclusive License Agreement (Atara Biotherapeutics, Inc.)
Issue Fee. (a) As initial payment for the rights received under this Agreement with respect to CTL Products, Licensee paid to Institute a fixed fee of three million dollars ($3,000,000) (the “Issue Fee”) within fifteen (15) business days following the Original Effective Date. The Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee. The Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.
(b) As initial payment for the rights received under this Agreement with respect to BKV/JCV-Specific CTL Products, Licensee will pay paid to Institute a fixed fee of [ * [***] (the “BKV BKV/JCV Issue Fee”) within fifteen (15) business days following the Execution First Restatement Date. The BKV BKV/JCV Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee. The BKV BKV/JCV Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.
Appears in 1 contract
Sources: Exclusive License Agreement (Atara Biotherapeutics, Inc.)
Issue Fee. (a) As initial payment for the rights received under this Agreement with respect to CTL Products, Licensee paid to Institute a fixed fee of three million dollars ($3,000,000) (the “Issue Fee”) within fifteen (15) business days following the Original Effective Date. The Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee. The Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.
(b) As initial payment for the rights received under this Agreement with respect to BKV/JCV-Specific CTL Products, Licensee will pay paid to Institute a fixed fee of [ * ] (the “BKV BKV/JCV Issue Fee”) within fifteen (15) business days following the Execution First Restatement Date. The BKV BKV/JCV Issue Fee is non-refundable and non-creditable against any other amounts, including but not limited to, Earned Royalties due to Institute by Licensee. The BKV BKV/JCV Issue Fee is in no way contingent on use or productivity of Patent Rights and Know-How Rights provided by Institute.
Appears in 1 contract
Sources: Exclusive License Agreement (Atara Biotherapeutics, Inc.)